PeptiDream Inc., a public Kanagawa-based biopharmaceutical company (“PeptiDream”) announced that it has entered into a collaboration with Merck & Co., Inc., Rahway, N.J., USA for the discovery and development of novel peptide therapeutics capable of neutralizing both the current SARS-CoV-2 virus (Coronavirus Disease “COVID19”) and potential future Coronavirus outbreaks.